Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bristol-Myers Squibb has said that data from a study of Baraclude showed that hepatitis B patients achieved viral suppression with the drug.
Subscribe to our email newsletter
These data showed that patients who experienced recurrent levels of hepatitis B virus in the blood after interruption of treatment with Baraclude also achieved liver enzyme (ALT) normalization.
In this study, 93% of patients who were re-treated with Baraclude had undetectable viral load – the level of the hepatitis B virus in the blood and 83% achieved liver enzyme normalization after 48 weeks of therapy.
“This study showed that when treated again with Baraclude for 48 weeks, patients achieved responses similar to those seen prior to treatment interruption, with safety results consistent with previously reported experience,” said Hakan Senturk, of the Ist.Univ.Cerrahpasa Tip Fak, Istanbul.
Discovered at Bristol-Myers Squibb, Baraclude is a nucleoside analogue indicated for the treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication with either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. Baraclude has been approved in more than 60 countries and regions around the world.